BILL Holdings (NYSE:BILL) Bolsa

BILL HOLDINGS INC

BILL Holdings

BILL Holdings Inc is a provider of software-as-a-service, cloud-based payments and spend and expense management products, which allow users to automate accounts payable and accounts receivable transactions, enable businesses to easily connect with their suppliers or customers to do business, eliminate expense reports, manage cash flows and improve back office efficiency. Initial Public Offering and Follow-on Offering.

Bill.com Holdings

HewlettPackard-Enterprise

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

BILL

FIVN

Las acciones más sobrevendidas del sector de tecnología presentan una oportunidad para comprar empresas infravaloradas.

¿Es ahora el momento de invertir? Las acciones sobrevendidas en tecnología con RSI bajo 30

Insider Trades

TCBS

Descubre las recientes compras de insiders y cómo podrían señalar oportunidades de inversión a largo plazo. Explora los movimientos clave.

BILL Holdings y otras 2 acciones que los insiders están comprando

BILL Holdings Inc

BILL IDENTITY LTD by BILL IDENTITY LTD

Billerud AB

BillionHappiness

The Ordinary Shares have been approved for listing on the NASDAQ Capital Market and are expected to commence trading on April 1, 2025, under the ticker symbol "ENGS."

IPOs

Energys Group Prices IPO Of 2.25M Ordinary Shares At $4.50 Per Ordinary Share

Management

Banco Macro Appoints Juan Parma As Its New CEO

Earnings

Maui Land & Pineapple 2024 EPS $(0.38) Down From $(0.15) YoY, Sales $11.56M Up From $9.29M YoY

These certifications will enable Springview Singapore to bid for small-scale public sector projects and the Company therefore expects that these certifications will allow Springview Singapore to significantly expand its addressable market.

SPHL

Springview's Singapore Subsidiary Secures Two New Important Government Certifications

GCTK

Glucotrack 2024 EPS $(68.44) Down From $(34.18) YoY

Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) has outperformed the market over the past 20 years by 5.89% on an annualized basis producing an average annual return of 13.93%. Currently, Union Pacific has a market capitalization of $141.58 billion. 
Buying $1000 In UNP: If an investor had bought $1000 of UNP stock 20 years ago, it would be worth $13,730.89 today based on a price of $236.24 for UNP at the time of writing.
<h3>Union Pacific's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743455708_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today

Microvast Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) reported quarterly losses of $(0.01) per share. This is a 75 percent increase over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $113.39 million which beat the analyst consensus estimate of $91.88 million by 23.41 percent. This is a 8.43 percent increase over sales of $104.58 million the same period last year.

Earnings Beats

MVST

Microvast Holdings Q4 2024 Adj EPS $(0.01) Up From $(0.04) YoY, Sales $113.39M Beat $91.88M Estimate

REBN

Reborn Coffee Q4 Sales $1.8M Up From $1.4M YoY

Seritage Growth Properties Q4 EPS $(0.22) Down From $0.08 YoY

FCX currently expects its consolidated copper sales for first-quarter 2025 to be in line with its January 2025 guidance of 850 million pounds and its gold sales for first quarter 2025 to be approximately 100 thousand ounces below its January 2025 guidance of 225 thousand ounces.
FCX is reviewing its annual consolidated sales guidance in connection with its routine quarterly forecast updates and does not currently expect a material change to its 2025 annual guidance.
 &nbsp;
 &nbsp;

Guidance

Freeport Says Q1 Copper And Gold Production Approximated Expectations; Expects No Material Impact On Annual Consolidated Sales Guidance

<h3>Gainers</h3>
<ul>
<li>SharpLink Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) stock increased by 37.5% to $0.4 during Monday's after-market session. The company's market cap stands at $2.7 million. </li>
<li>Sportsman's Warehouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWH#NASDAQ">SPWH</a>) stock rose 15.68% to $1.15. The market value of their outstanding shares is at $43.6 million. </li>
<li>PVH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) stock moved upwards by 15.51% to $74.67. The market value of their outstanding shares is at $4.1 billion. The company's, Q4 earnings came out today. </li>
<li>Lazydays Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GORV#NASDAQ">GORV</a>) stock increased by 14.05% to $0.37. The company's market cap stands at $40.6 million. As per the press release, Q4 earnings came out today. </li>
<li>MKDWell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKDW#NASDAQ">MKDW</a>) shares increased by 11.66% to $0.33. The market value of their outstanding shares is at $6.1 million. </li>
<li>Solo Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTC#NYSE">DTC</a>) shares moved upwards by 10.66% to $0.19. The market value of their outstanding shares is at $10.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>LightInTheBox Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LITB#NYSE">LITB</a>) stock declined by 14.5% to $1.71 during Monday's after-market session. The company's market cap stands at $190.0 million. The company's, Q4 earnings came out 4 days ago. </li>
<li>Interactive Strength (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNR#NASDAQ">TRNR</a>) stock declined by 10.57% to $1.1. The market value of their outstanding shares is at $1.6 million. </li>
<li>China Liberal Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLEU#NASDAQ">CLEU</a>) shares fell 9.51% to $1.9. The company's market cap stands at $511.8 million. </li>
<li>Color Star Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADD#NASDAQ">ADD</a>) shares declined by 6.77% to $0.66. </li>
<li>Mullen Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) stock fell 6.67% to $0.1. </li>
<li>Allurion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) stock fell 6.24% to $3.01. The company's market cap stands at $17.9 million. As per the news, the Q4 earnings report came out 3 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ALUR

CLEU

GORV

LITB

MKDW

MULN

SBET

SPWH

TRNR

12 Consumer Discretionary Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock rose 198.8% to $0.78 during Monday's after-market session. The company's market cap stands at $12.1 million. As per the press release, Q4 earnings came out today. </li>
<li>Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) shares rose 51.02% to $70.3. The company's market cap stands at $382.2 million. As per the press release, Q4 earnings came out today. </li>
<li>Compass Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPX#NASDAQ">CMPX</a>) stock rose 18.42% to $2.25. The company's market cap stands at $309.5 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) stock moved upwards by 17.7% to $1.13. The market value of their outstanding shares is at $6.6 million. The company's, Q4 earnings came out 2 days ago. </li>
<li>Bionano Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>) stock moved upwards by 16.29% to $3.24. The market value of their outstanding shares is at $8.8 million. As per the press release, Q4 earnings came out today. </li>
<li>Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) shares moved upwards by 10.48% to $0.55. The market value of their outstanding shares is at $9.3 million. The company's, Q4 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>AquaBounty Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQB#NASDAQ">AQB</a>) stock fell 11.2% to $0.61 during Monday's after-market session. The market value of their outstanding shares is at $2.3 million. </li>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) shares declined by 8.9% to $2.51. The company's market cap stands at $3.7 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) shares decreased by 8.61% to $0.85. The market value of their outstanding shares is at $60.8 million. </li>
<li>Enzo Biochem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENZ#NYSE">ENZ</a>) stock declined by 7.83% to $0.34. The market value of their outstanding shares is at $17.8 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares decreased by 6.67% to $0.56. The market value of their outstanding shares is at $2.5 million. </li>
<li>Adverum Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADVM#NASDAQ">ADVM</a>) stock declined by 6.64% to $4.08. The market value of their outstanding shares is at $84.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADVM

BIAF

BNGO

CMPX

CTOR

EVOK

NUTX

PSTV

TLPH

12 Health Care Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Microvast Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) shares rose 27.4% to $1.49 during Monday's after-market session. The company's market cap stands at $482.6 million. As per the press release, Q4 earnings came out today. </li>
<li>Expion360 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) stock moved upwards by 6.4% to $0.96. The company's market cap stands at $3.0 million. The company's, Q4 earnings came out today. </li>
<li>VCI Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCIG#NASDAQ">VCIG</a>) shares increased by 5.17% to $0.44. The company's market cap stands at $20.7 million. </li>
<li>BioNexus Gene Lab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGLC#NASDAQ">BGLC</a>) stock rose 5.12% to $0.25. The company's market cap stands at $4.4 million. </li>
<li>Westwater Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/WWR#AMEX">WWR</a>) shares increased by 5.11% to $0.58. The company's market cap stands at $41.3 million. </li>
<li>WANG &amp; LEE Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) shares increased by 5.01% to $0.28. The market value of their outstanding shares is at $6.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>OneConstruction Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONEG#NASDAQ">ONEG</a>) stock decreased by 9.7% to $2.05 during Monday's after-market session. The market value of their outstanding shares is at $26.6 million. </li>
<li>Silynxcom (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SYNX#AMEX">SYNX</a>) stock declined by 8.84% to $3.3. The market value of their outstanding shares is at $17.6 million. </li>
<li>ESS Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWH#NYSE">GWH</a>) shares decreased by 8.59% to $2.98. The company's market cap stands at $35.4 million. The company's, Q4 earnings came out today. </li>
<li>Elong Power Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELPW#NASDAQ">ELPW</a>) stock decreased by 6.85% to $0.69. The market value of their outstanding shares is at $34.5 million. </li>
<li>Singularity Future Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGLY#NASDAQ">SGLY</a>) shares decreased by 5.88% to $0.72. The company's market cap stands at $3.0 million. </li>
<li>Greenland Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTEC#NASDAQ">GTEC</a>) shares decreased by 5.72% to $1.65. The company's market cap stands at $22.4 million. As per the press release, Q4 earnings came out 3 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BGLC

ELPW

GTEC

ONEG

SGLY

SYNX

VCIG

WLGS

XPON

12 Industrials Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Cloudastructure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSAI#NASDAQ">CSAI</a>) shares rose 36.3% to $6.05 during Monday's after-market session. The market value of their outstanding shares is at $93.5 million. </li>
<li>Progress Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRGS#NASDAQ">PRGS</a>) shares moved upwards by 7.94% to $55.6. The company's market cap stands at $2.3 billion. As per the press release, Q1 earnings came out today. </li>
<li>MultiSensor AI Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSAI#NASDAQ">MSAI</a>) stock rose 7.33% to $1.0. The company's market cap stands at $32.0 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Inuvo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INUV#AMEX">INUV</a>) stock moved upwards by 7.01% to $0.38. The market value of their outstanding shares is at $53.3 million. </li>
<li>GSI Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSIT#NASDAQ">GSIT</a>) shares moved upwards by 6.4% to $2.16. The company's market cap stands at $55.2 million. </li>
<li>LivePerson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPSN#NASDAQ">LPSN</a>) shares increased by 6.34% to $0.85. The market value of their outstanding shares is at $77.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cambium Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMBM#NASDAQ">CMBM</a>) stock fell 30.6% to $0.49 during Monday's after-market session. The company's market cap stands at $13.8 million. </li>
<li>Soluna Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNH#NASDAQ">SLNH</a>) shares fell 17.84% to $0.52. The market value of their outstanding shares is at $5.5 million. </li>
<li>Gorilla Tech Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRRR#NASDAQ">GRRR</a>) stock decreased by 9.36% to $26.83. The market value of their outstanding shares is at $495.4 million. As per the press release, FY earnings came out today. </li>
<li>AmpliTech Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPG#NASDAQ">AMPG</a>) shares decreased by 8.39% to $1.42. The company's market cap stands at $27.9 million. </li>
<li>Saverone 2014 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>) stock fell 5.67% to $2.83. The company's market cap stands at $1.5 million. </li>
<li>Signing Day Sports (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SGN#AMEX">SGN</a>) stock fell 5.4% to $0.66. The market value of their outstanding shares is at $1.2 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMPG

CMBM

CSAI

GRRR

GSIT

INUV

LPSN

Infrared Cameras Holdings, Inc. - Common Stock

MSAI

PRGS

SLNH

SVRE

12 Information Technology Stocks Moving In Monday's After-Market Session

Babcock &amp; Wilcox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BW#NYSE">BW</a>) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.01) by 5100 percent. The company reported quarterly sales of $200.80 million which missed the analyst consensus estimate of $213.07 million by 5.76 percent. This is a 11.62 percent decrease over sales of $227.20 million the same period last year.

Earnings Misses

Babcock & Wilcox Q4 2024 GAAP EPS Continuing Operations $(0.52), Sales $200.80M

In the current session, Littelfuse Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFUS#NASDAQ">LFUS</a>) is trading at $196.74, after a 2.10% drop. Over the past month, the stock decreased by 8.76%, and in the past year, by 16.31%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1743454881_0.png" alt="Past Year Chart" />

<h3>How Does Littelfuse P/E Compare to Other Companies?</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Littelfuse has a better P/E ratio of 50.24 than the aggregate P/E ratio of 40.76 of the Electronic Equipment, Instruments &amp; Components industry. Ideally, one might believe that Littelfuse Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1743454881_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

LFUS

Price Over Earnings Overview: Littelfuse

In the latest quarter, 8 analysts provided ratings for Halliburton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>), showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $34.25, a high estimate of $41.00, and a low estimate of $29.00. A decline of 8.37% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1743454868_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Halliburton among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$29.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Keith Mackey</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Kurt Hallead</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$35.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$37.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$30.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>James West</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$35.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Lloyd Byrne</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$41.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$33.00</td>
<td>$35.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Halliburton. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Halliburton compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Halliburton's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Halliburton's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HAL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Halliburton analyst ratings.</a>
<h2>Get to Know Halliburton Better</h2>
Halliburton Co is North America's largest oilfield service company as measured by market share. Despite industry fragmentation, it holds a leading position in the hydraulic fracturing and completions market, which makes up nearly half of its revenue. It also holds strong positions in other service offerings like drilling and completions fluids, which leverages its expertise in material science, as well as the directional drilling market. While we consider SLB the global leader in reservoir evaluation, we think Halliburton leads in any activity from the reservoir to the wellbore. The firm's innovations have helped multiple producers lower their development costs per barrel of oil equivalent, with techniques that have been homed in over a century of operations.
<h3>Halliburton: Financial Performance Dissected</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Negative Revenue Trend: Examining Halliburton's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -2.25% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Energy sector.
Net Margin: Halliburton's net margin is impressive, surpassing industry averages. With a net margin of 10.96%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Halliburton's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.91% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Halliburton's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.42%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.82.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

8 Analysts Assess Halliburton: What You Need To Know

Across the recent three months, 8 analysts have shared their insights on T. Rowe Price Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TROW#NASDAQ">TROW</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated T. Rowe Price Group and provided 12-month price targets. The average target is $112.12, accompanied by a high estimate of $121.00 and a low estimate of $100.00. This current average has decreased by 4.89% from the previous average price target of $117.88. 
<img src="https://www.benzinga.com/files/images/story/2025/1743454853_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of T. Rowe Price Group among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris Allen</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$121.00</td>
<td>$126.00</td>
</tr>
<tr>
<td>Aidan Hall</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$113.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$116.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$105.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$113.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$118.00</td>
<td>$124.00</td>
</tr>
<tr>
<td>Aidan Hall</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$111.00</td>
<td>$116.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to T. Rowe Price Group. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of T. Rowe Price Group compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of T. Rowe Price Group's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of T. Rowe Price Group's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TROW/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on T. Rowe Price Group analyst ratings.</a>
<h2>All You Need to Know About T. Rowe Price Group</h2>
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load us and international stock, hybrid, bond, and money market funds. At the end of October 2024, the firm had $1.607 trillion in managed assets, composed of equity (51%), balanced (34%), fixed-income and money market (12%), and alternative (3%) offerings. Approximately two thirds of managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a us-based asset manager, deriving less than 10% of its AUM from overseas.
<h3>T. Rowe Price Group: Financial Performance Dissected</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: T. Rowe Price Group's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 11.11%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: T. Rowe Price Group's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 23.47%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 4.16%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 3.15%, the company showcases effective utilization of assets.
Debt Management: T. Rowe Price Group's debt-to-equity ratio is below the industry average. With a ratio of 0.03, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TROW

Expert Outlook: T. Rowe Price Group Through The Eyes Of 8 Analysts

13 analysts have shared their evaluations of Dynatrace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Dynatrace and provided 12-month price targets. The average target is $63.31, accompanied by a high estimate of $69.00 and a low estimate of $57.00. Observing a 0.49% increase, the current average has risen from the previous average price target of $63.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1743454838_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Dynatrace by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$60.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$69.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Thomas Blakey</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$57.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$67.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$62.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$69.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Thomas Blakey</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$57.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$67.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Sanjit Singh</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$62.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Thomas Blakey</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Neutral</td>
<td>$58.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Dynatrace. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Dynatrace compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Dynatrace's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Dynatrace's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/DT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Dynatrace analyst ratings.</a>
<h2>Discovering Dynatrace: A Closer Look</h2>
Dynatrace is a cloud-native company that focuses on analyzing machine data. Its product portfolio, delivered as software as a service, allows a client to monitor and analyze its entire IT infrastructure. Dynatrace's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to use it for a variety of applications throughout their businesses.
<h3>Dynatrace: Delving into Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Dynatrace's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 19.47%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Dynatrace's net margin is impressive, surpassing industry averages. With a net margin of 82.94%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Dynatrace's ROE stands out, surpassing industry averages. With an impressive ROE of 15.4%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Dynatrace's ROA excels beyond industry benchmarks, reaching 10.24%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.03.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Dynatrace Stock: Analyst Perspectives (13 Ratings)

In the preceding three months, 4 analysts have released ratings for Progyny (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGNY#NASDAQ">PGNY</a>), presenting a wide array of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Progyny and provided 12-month price targets. The average target is $24.75, accompanied by a high estimate of $28.00 and a low estimate of $23.00. This current average reflects an increase of 35.02% from the previous average price target of $18.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1743454830_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of Progyny by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Larsen</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$28.00</td>
<td>-</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$23.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Michael Cherny</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Progyny. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Progyny compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Progyny's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Progyny's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PGNY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Progyny analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Progyny Better</h2>
Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.
<h3>Unraveling the Financial Story of Progyny</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Progyny's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 10.55% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Progyny's net margin excels beyond industry benchmarks, reaching 3.53%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Progyny's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.46% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.66%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.05, Progyny adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PGNY

Analyst Expectations For Progyny's Future

Press Releases

BILL to Participate in Upcoming Investor Conference

BILL to Offer $1.0 Billion of Convertible Senior Notes due 2030

BILL Announces Pricing of Upsized Offering of $1.25 Billion of 0% Convertible Senior Notes Due 2030

BILL Announces Closing of Offering of $1.4 Billion of 0% Convertible Senior Notes due 2030, Including Full Exercise of Initial Purchasers' $150.0 Million Option to Purchase Additional Notes

BILL Unveils 1099 Form Filing Solution for SMBs

Lennox International Set to Join S&P 500 and BILL Holdings to Join S&P MidCap 400

Comments

BILL Holdings

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL